A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: Male

Summary

A study for the treatment of hormone refractory prostate cancer (HRPC) in patients previously treated with chemotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Collaborator: Astellas Pharma US, Inc.

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed prostate cancer.

• Prior chemotherapy regimen for prostate cancer

Exclusion Criteria:

• History of other malignancy in the last 5 years

• Major surgery within the past 21 days